The Japanese pharmaceutical industry, a vital component of global innovation, faces a talent gap that resonates across multinational corporations. While Japan possesses a wealth of highly skilled professionals, a notable communication disparity impedes recruitment and career advancement, particularly in global…
BUSINESS
Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
Astellas Pharma suffered an 8% decline on its first-quarter sales as strong performances from the cancer drug Xtandi (enzalutamide) and FLT3 inhibitor Xospata (gilteritinib) failed to counter the negative impact of deal terminations and COVID-19. According to the company’s quarterly…
To read the full story
Related Article
- Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
April 28, 2025
- Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets
October 31, 2024
- Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
- Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
April 26, 2024
- Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
April 15, 2024
- Astellas Slashes FY2023 Veozah Forecast as Vertical Start-Up Plan Stumbles
February 6, 2024
- Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
April 28, 2023
- Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
February 7, 2023
- Astellas’ Half-Year Revenue Up 17% on FX Boon; Xtandi US Sales Stall
November 2, 2022
- Astellas’ Earnings Hit by FX as Cost Rate Worsens on Overseas Inventories
August 2, 2022
- Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
- Astellas Sees Surge in 9-Month Revenue on Xtandi Growth, US Market Recovery
February 3, 2022
- Astellas’ Half-Year Revenue Up Nearly 6% on Bullish Xtandi
November 1, 2021
- Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
August 2, 2021
- Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
April 28, 2021
- Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
November 2, 2020
- Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
May 15, 2020
BUSINESS
- Taking on Solid Tumors - 6: Pfizer Japan Sees Rosy Uptake with Elrexfio, Mulling Bringing Bispecific Assets for Solid Cancers Too
June 18, 2025
- Otsuka’s Therapeutic App for Depression Now Available in Great Britain
June 18, 2025
- Alfresa Teams Up with HekaBio, Swanielle to Fight Drug Lag/Loss
June 18, 2025
- Axcelead, A2 Healthcare Pair Up to Eliminate Drug Loss
June 18, 2025
- Chugai Halts Dosing of Non-Ambulatory Patients in DMD Gene Therapy Trial after 2 Deaths Overseas
June 17, 2025
Following the launch of two new therapies since last year, Japan has seen fresh moves in drug development for amyotrophic…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…